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ARTICLE
Engineering brain activity patterns by
neuromodulator polytherapy for treatment
of disorders
Mostafa Ghannad-Rezaie 1,2, Peter M. Eimon1, Yuelong Wu1 & Mehmet Fatih Yanik1,2
Conventional drug screens and treatments often ignore the underlying complexity of
brain network dysfunctions, resulting in suboptimal outcomes. Here we ask whether we can
correct abnormal functional connectivity of the entire brain by identifying and combining
multiple neuromodulators that perturb connectivity in complementary ways. Our approach
avoids the combinatorial complexity of screening all drug combinations. We develop a high-
speed platform capable of imaging more than 15000 neurons in 50ms to map the entire brain
functional connectivity in large numbers of vertebrates under many conditions. Screening a
panel of drugs in a zebraﬁsh model of human Dravet syndrome, we show that even drugs
with related mechanisms of action can modulate functional connectivity in signiﬁcantly dif-
ferent ways. By clustering connectivity ﬁngerprints, we algorithmically select small subsets of
complementary drugs and rapidly identify combinations that are signiﬁcantly more effective
at correcting abnormal networks and reducing spontaneous seizures than monotherapies,
while minimizing behavioral side effects. Even at low concentrations, our polytherapy per-
forms superior to individual drugs even at highest tolerated concentrations.
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Treatment-resistant neurological and psychiatric disordersare a major public health problem impacting many mil-lions of people worldwide. Existing therapeutics are inef-
fective in 40% of patients with anxiety disorders1, 30–40% of
patients with depression2, and 20–30% of patients with
epilepsy3–5, 30% of patients with schizophrenia6, and 40% of
patients with OCD7. Although drug discovery often relies on
identifying novel therapeutics with improved efﬁcacy and fewer
side effects, combining existing drugs (i.e. polytherapy) may
provide better outcomes. Polytherapy utilizes two or more drugs,
often with different mechanisms of action (MOAs), in order to
achieve higher efﬁcacy and reduced side effects. Polytherapy is
already widely used in the clinical treatment of many disorders.
For example, there is strong evidence for synergism when
valproate and lamotrigine are used as a duotherapy for partial and
generalized epilepsy8,9. A large-scale study of patients with
bipolar disorder found that 33% were put on a polytherapy
regimen (deﬁned as two or more major psychotropic drugs)
beginning with their initial prescription10. Even in the case of
schizophrenia and related psychoses, where treatment guidelines
recommend monotherapy, it is estimated that ~40–60% of
patients wind up receiving antipsychotic polytherapy11. In addi-
tion, it is increasingly apparent that even many monotherapies
can have more than one MOA at therapeutic concentrations. For
example, there is convincing evidence that many modern anti-
epileptic agents—including felbamate, topiramate, levetiracetam,
and zonisamide—work through multiple targets12.
Unfortunately, empirical approaches for selecting the optimal
polytherapy combinations are challenging due to the combina-
torial complexity of potential drugs and dose ranges. As a result,
doctors and clinicians often make choices based on a variety of
rational criteria such as pharmacokinetic and pharmacodynamic
compatibility, lack of side effects, or selecting drugs with diver-
gent MOAs13–15. This approach is hindered by an incomplete
understanding of MOAs and/or the underlying pathophysiology
of the disorder. An empirical alternative to rational polytherapy
would involve testing all potential drug combinations in animal
models and moving the most promising ones into clinical trials.
Such a strategy is impractical for evaluating more than a handful
of duotherapy options in standard rodent behavioral models,
which are both expensive and low-throughput. High-throughput
behavior-based assays in zebraﬁsh have been used in recent years
for neuroactive drug screens16–18 and offer a potential solution
for large-scale combinatorial screening. However, behavioral
screens are highly reductive, typically employing simple loco-
motor assays as surrogates for more complex neurological states.
Additionally, even behavioral assays with very high throughput
remain unsuitable for combinatorial screening of large numbers
of compounds. Approximately 1500 drugs have received approval
from the U.S. Food and Drug Administration19. Empirically
testing all possible duotherapy options even in a single disease
model would involve 1.1 × 106 combinations (i.e. ~107 animal
tests). Expanding polytherapy screens to include additional dis-
ease models, multiple drug concentrations, larger chemical
libraries, or to explore three- or four-way combinations further
increases the difﬁculty of such screens.
Here, we describe an alternative polytherapy screening strategy
that addresses these challenges using brain-wide functional con-
nectivity patterns. We apply our approach to a zebraﬁsh model of
Dravet syndrome, an intractable genetic epilepsy in humans.
Rather than directly testing all possible drug combinations, we
ﬁrst identify how only the individual drugs alter the functional
connectivity between brain areas. Broadly speaking, two areas are
considered functionally connected if the time series of their
neuronal activity (as measured by a genetically encoded calcium
indicator (GCaMP)) is highly correlated. Such functional
connectivity has been extensively investigated over the past two
decades in humans and animal models, typically using functional
magnetic resonance imaging (fMRI). Changes in functional
connectivity have been described in numerous neurological and
psychiatric disorders, including epilepsy, Alzheimer's disease,
autism, schizophrenia, major depressive disorder, and post-
traumatic stress disorder20–27. Additionally, connectivity is
altered in short- and long-term responses to neuroactive
substances28,29, meaning that it offers a direct multi-parametric
readout of how brain activity is affected by pharmacological
interventions. In humans, functional connectivity studies conﬁrm
that even focal epilepsies produce widespread changes in con-
nectivity patterns20, and we report here for the ﬁrst time the
presence of such nontrivial network dysfunctions in epileptic
zebraﬁsh brains. Next, using a novel clustering algorithm, we
classify drugs based on their functional connectivity ﬁngerprints
to identify hits that correct complimentary facets of the abnor-
mal brain-wide network in mutant zebraﬁsh. This allows us to
identify polytherapy combinations that are likely to produce
synergistic effects based on their ability to target distinct aspects
of the underlying network dysfunction, rather than simply
combining drugs with different suspected MOAs. Having thus
reduced the tremendously large parameter space to a manageable
number of options, all top polytherapy combinations can be easily
evaluated over a range of doses and tested in follow-up assays for
efﬁcacy and side effects. Our approach offers a powerful new
classiﬁcation means for drugs based on in vivo brain activity
patterns, which is in many respects complementary to traditional
MOA-based approaches.
Although our approach is likely applicable to different animal
models, we tested it in zebraﬁsh larvae by taking advantage of the
recent advances in light-sheet microscopy for fast cellular-
resolution imaging of neuronal activity30–32. In order to rapidly
assess the effects of compounds on in vivo brain activity with high
spatiotemporal resolution, we implemented (1) a high speed
light-sheet microscope that can image the brain at single-cell
resolution in 50 ms (~15 % of all neurons in each zebraﬁsh larva’s
brain is imaged), (2) a high-throughput ﬂuidic platform capable
of handling and imaging large numbers of larvae under multiple
treatment conditions, and (3) algorithms that automatically reg-
ister the resultant data to a 3D anatomical zebraﬁsh brain atlas for
brain-wide connectivity ﬁngerprint analysis. Among the hits that
we identiﬁed using our approach, the best duotherapy combi-
nations achieve signiﬁcantly greater seizure reduction than any
monotherapy alone. Even at their highest tolerated doses, we ﬁnd
that monotherapies are unable to match the efﬁcacy achieved by
our best polytherapy regimens at substantially lower concentra-
tions with minimal side effects. Our results demonstrate the
power of network functional connectivity analysis for the dis-
covery of neuroactive drugs, and in particular for polydrug
screening.
Results
High-throughput mapping of brain activity patterns. To enable
large-scale drug screens based on neural activity in zebraﬁsh
expressing genetically encoded calcium indicators, we designed
and built a high-speed light-sheet microscopy platform paired
with peripheral ﬂuidics for rapidly processing large numbers of
larvae under multiple treatment conditions (Fig. 1). The illumi-
nation and detection arms of our platform expand on previous
light-sheet microscope designs30 and are detailed in the Methods
section. In order to immobilize and precisely position non-
anesthetized non-paralyzed zebraﬁsh larvae for analysis, we
devised a process through, which larvae can be rapidly embedded
in dual-layer agarose cylinders (Fig. 1; see Methods section for
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details)33. Embedded larvae remain healthy and develop normally
for up to 12 h, allowing long-term assessment of the effects of
drug-induced changes on brain activity (Supplementary Fig. 1).
The outer diameter of the agar cylinders is size-matched to the
imaging chamber capillary and all peripheral ﬂuidic tubing.
When not being imaged, agar-embedded larvae are housed in
incubation reservoirs connected to the light-sheet imaging
chamber through a series of ﬂuidic tubes and valves. Initially,
incubation reservoirs are ﬁlled with E3 embryo medium. All
larvae from a reservoir are loaded in turn into the light-sheet
imaging chamber using computerized syringe pumps as explained
in the Methods section and illustrated in Supplementary Fig. 2.
Each larva is imaged to acquire pre-drug-exposure neural activity
data and the image is registered to an atlas (see Methods section).
Once all larvae from an incubation reservoir have been imaged,
they are returned to the reservoir and the drug of interest is
added. After a 4+ h incubation time, the entire loading and
imaging process is repeated to assess post-exposure neural
activity. Once the second imaging session is complete, larvae can
either be returned to the incubation reservoir or, as in the fol-
lowing experiments, collected for genotyping. By utilizing mul-
tiple incubation reservoirs in a staggered manner, it is possible to
achieve continuous imaging of samples. The number of larvae
that can be housed per reservoir depends in part on the desired
experimental parameters. In the following experiments, we use
ﬁve larvae per reservoir and an imaging time of 18 min per larva,
meaning that all larvae in a given reservoir are analyzed between
4.0 and 5.5 h post-exposure with ~90 min separating the ﬁrst and
last larva imaged. For experiments requiring greater temporal
precision, fewer larvae can be distributed between a larger
number of incubation reservoirs.
Brain-wide imaging reveals abnormal functional connectivity.
In humans, mutations in the voltage-gated sodium ion channel
alpha subunit 1 (SCN1A; OMIM *182389) are associated with a
spectrum of childhood neurological dysfunctions including Dra-
vet syndrome34,35. In zebraﬁsh, the scn1lab gene encodes a
voltage-gated sodium ion channel orthologous to mammalian
SCN1A and related SCN family members. The scn1lab loss-of-
function mutation s552 (previously referred to as double
indemnity or didy) causes spontaneous seizures in homozygous
mutant zebraﬁsh larvae beginning at ~4 dpf. Mutants respond to
many of the same anti-epileptic drugs (AEDs) used to treat
Dravet syndrome in humans16. In addition to spontaneous sei-
zures, we ﬁnd that scn1lab mutants experience photosensitive
seizures that can be triggered by light pulses, as we recently
demonstrated33. In order to deliver precisely-timed light stimuli,
we use a computer-controlled LED illuminator programmed to
administer two brief (500 ms) light pulses separated by a 1 s
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Fig. 1 High-throughput platform for functional brain connectivity-based drug screening. The platform consists of multiple incubation reservoirs in which
zebraﬁsh larvae (captured in a dual-layer polymer pellet) can be treated with compounds of interest and rapidly transferred back and forth and positioned
in the imaging chamber of a high-speed light-sheet microscope. The platform has six parts: (1) an illumination arm consisting of a 488 nm ﬁber laser, a 2D
galvo scanner, a tube lens, a shutter, and a low NA ×4 objective. (2) A light-stimulus arm, consisting of a halogen lamp, a ﬁlter, a tube lens, a fast shutter to
deliver brief light pulses, and a ×4 objective. (3) A detection arm, consisting of a ×16 water immersion objective, a piezo scanner, a 525 nm ﬂuorescent
ﬁlter, a tube lens, and a high speed sCMOS camera. (4) An imaging chamber, consisting of an ultra-thin wall glass capillary running through a custom-
made watertight glass-sided aluminum chamber. The glass capillary is connected to a stepper motor for rotational alignment of the larva. (5) Multiple
reservoirs for incubating agarose-embedded zebraﬁsh larvae in drugs. When an incubation chamber is connected to the imaging chamber (via opening a
series of pinch valves V1-V5), a syringe pump loads larvae that have been pre-embedded in a dual-layer polymer pellet into the imaging chamber one at a
time. (6) Two syringe pumps used for transferring larvae between incubation reservoirs and the imaging chamber and for cleaning the imaging chamber
between each imaging cycle
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interval. When homozygous scn1lab mutant larvae are exposed to
light stimuli, forebrain local ﬁeld potential (LFP) recordings
display multiple high-amplitude peaks commencing shortly after
the onset of each stimulus and persisting for several seconds
(Supplementary Fig. 3a). Similar spontaneous seizure-like bursts
are observed periodically in mutant larvae in the absence of light
stimuli (Supplementary Fig. 3b), as described previously in the
literature16. In contrast, sibling controls (i.e. age-matched larvae
from the same clutch that are either wild-type or heterozygous for
the s552 allele) have a markedly different response, characterized
by single lower-amplitude peaks (Supplementary Fig. 3a) that
become progressively diminished with each subsequent pre-
sentation of the light stimulus (Supplementary Fig. 3c). Addi-
tionally, mutants exhibit short rapid bursts of seizure-like
locomotor activity that persist for ~5 s after each stimulus,
whereas sibling controls show almost no perceptible increase in
locomotor activity (Supplementary Videos 1 and 2). To quantify
light-triggered swimming behavior, we record larvae under
infrared illumination using an automated tracking platform and
calculate the mean swimming velocity during 5-s intervals com-
mencing with the onset of each light stimulus. Light-triggered
locomotor activity is signiﬁcantly higher in mutants than in
siblings (Supplementary Fig. 4). Importantly, light-triggered sei-
zure-like bursts are observed in LFP recordings from mutant
larvae that have been paralyzed with pancuronium bromide,
conﬁrming they are not attributable to motion artifacts due to
increased locomotor activity in mutants (Supplementary Fig. 5).
Photosensitivity appears to be a general feature of scn1lab loss-of-
function mutations, as we observe similar abnormal light-
triggered phenotypes in both the original scn1labs552 line
(which contains a p.Met1208Arg missense mutation in ion
channel domain III) and in a second scn1lab line (sa16474) that
was generated as part of the Zebraﬁsh Mutation Project (Sup-
plementary Fig. 4). This second line contains a C to A mutation at
position 1386 of the scn1lab open reading frame, resulting in a
premature stop codon at the position between ion channel
domains I and II and presumably resulting in a nonfunctional
protein33. This photosensitive phenotype is consistent with
Dravet syndrome in humans, where photosensitive seizures have
been reported in 30–40% of patients and are often associated with
more severe outcomes36–38.
We took advantage of photosensitivity, which allows us to
control the precise timing of seizures, to image brain activity
patterns before, during, and after seizures using light-sheet
microscopy. This was done by ﬁrst crossing the scn1labs552
mutation onto a transgenic line expressing the genetically
encoded calcium indicator GCaMP5G under the control of the
pan-neuronal elavl3 promoter [Tg(elavl3: GCaMP5G)]39. At 5
dpf, larvae are embedded in dual-layer agarose cylinders and
loaded into our high-throughput light-sheet platform for brain-
wide activity imaging. In order to analyze neural activity under
various states, imaging is carried out over the course of 18 min
using the parameters outlined in Fig. 2a. For the ﬁrst 10 min,
larvae are imaged in the absence of any seizure-inducing white
light stimuli (pre-stimulus state) to assess resting state activity.
Seizures are then triggered in mutant larvae using the stimulus
parameters described previously (two 500 ms pulses of light
separated by a 1 s interval), which are presented every 2 min over
the course of the remaining 8 min For subsequent analysis, this
portion of the imaging session is separated into an early post-
stimulus state (0–60 s after the presentation of each light
stimulus) and a late post-stimulus state (60–120 s after presenta-
tion), as indicated in Fig. 2a. Immediately following light stimuli,
we see a signiﬁcant increase in simultaneous GCaMP ﬂuorescence
activity in mutant larvae relative to wild-type sibling controls
(Fig. 2b, Supplementary Video 3–6). To conﬁrm that abnormal
light-triggered GCaMP activity in scn1lab mutants correlates with
electrophysiological hallmarks of seizures, we recorded forebrain
LFPs from agar-embedded larvae subjected to the same light
stimulus parameters (Fig. 2a), allowing us to compare timestamp-
synchronized LFP and GCaMP recordings in independent larvae
(Fig. 2b).
Although light-triggered increase in GCaMP ﬂuorescence
offers a reliable metric for detecting seizures, it remains a highly
reductive readout that fails to take into account alterations to
functional networks during non-seizing intervals and in response
to drug treatment. Functional connectivity, which is deﬁned as
the temporal correlation in activity between spatially separated
brain areas, offers a powerful multi-parametric tool for
comprehensively analyzing brain-wide functional imaging data-
sets. Importantly, functional connectivity maps are known to be
altered under various behavioral states27, making them particu-
larly useful for evaluating how drugs modulate multiple aspects of
brain activity and for benchmarking outcomes relative to wild-
type connectivity maps. Although functional connectivity is
typically studied using fMRI, which uses blood oxygenation level-
dependent (BOLD) contrast imaging as an indirect readout of
neural activity40, we instead employ GCaMP5 to directly monitor
the calcium signals that reﬂect neuronal spiking with much
higher temporal and spatial resolution. Calcium signals have
previously been used to map long-range functional connections
between cortical areas in GCaMP3 transgenic mice41, and a
recent study conﬁrms that both calcium indicators and
hemodynamic signals yield similar spatial maps of connectivity
across the entire brain in mice42.
In order to use functional connectivity patterns for drug
screening, we ﬁrst use k-means clustering43 to identify
individual neurons (supervoxels) in the image and then we
determine the correlation of activity between all pairs of neurons
in all areas in our brain atlas (see Methods for details). Finally, we
calculate the mean absolute correlation coefﬁcient in order to
generate a single metric for each pair of areas during each
state. Using this approach, we ﬁnd that there are clear differences
in functional connectivity between scn1lab mutants and
sibling controls during all three behavioral states: pre-stimulus,
early post-stimulus, and late post-stimulus (Supplementary
Fig. 6).
Identifying neuromodulators to normalize brain connectivity.
In order to identify the most promising compounds for anti-
epileptic screening, we previously used a simple behavioral metric
(mean light-triggered locomotor velocity) to rapidly evaluate a
diverse chemical library and identify compounds with potential
therapeutic activity in the photosensitive scn1labs552 line33. Our
starting library contained 154 compounds including AEDs,
neuroactive compounds targeting a wide spectrum of neuro-
transmitter pathways, and compounds that we identiﬁed as
potential binders to human SCN1A and SCN8A based on an in
silico analysis of protein pocket similarity44,45. Prior to
the screening, all compounds were ﬁrst assessed for toxicity at a
concentration of 100 μM. Those exhibiting overt toxicity at 4 h
post-exposure based on reduced/absent touch response were
retested at lower concentrations until a maximum tolerated dose
was found. From this collection, we selected 24 compounds for
in-depth functional connectivity analysis based on their ability to
reduce abnormal light-triggered locomotor activity in mutants by
at least 50% (Supplementary Table 1).
We then performed neural activity imaging to evaluate the
ability of these compounds to correct abnormal connectivity in
mutant larvae. Compound screening is carried out on 5 dpf larvae
embedded in dual-layer agarose cylinders using a minimum of
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ﬁve homozygous mutants and ﬁve sibling controls per
compound. Prior to compound exposure, light-sheet imaging is
performed on all larvae to establish baseline functional con-
nectivity data for each test group. During pre-exposure imaging,
homozygous mutants can be reliably distinguished from sibling
controls based on the intensity and duration of GCaMP activity.
Immediately after the acquisition of the baseline recording,
embedded larvae are transferred from the light-sheet imaging
chamber into drug incubation chambers containing test com-
pounds at the speciﬁed concentrations using our high-throughput
platform. Larvae are incubated in test compounds plus 1%
dimethyl sulfoxide (DMSO) for 4+ h, at which point they are
transferred back into the imaging chamber and a post-exposure
recording is performed. During both baseline and post-exposure
recordings, larvae are subjected to the light-stimulus parameters
described previously (Fig. 2a). Following post-exposure imaging,
larvae are collected and processed for PCR genotyping, as it is not
always possible to distinguish sibling controls from mutants that
have been treated with highly effective compounds based on
visual inspection of the GCaMP response.
A unique connectivity ﬁngerprint is then generated for each
compound that incorporates normalized inter-area correlations
from all three states: pre-stimulus, early post-stimulus, and late
post-stimulus. The resultant ﬁngerprint comprises 165 metrics
(i.e. 55 pairs of brain areas; three states), with each metric
representing the average of 5+ larvae. We then use hierarchical
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Fig. 2 Functional brain connectivity ﬁngerprints identify polytherapy candidates. a Schematic representation of the light stimulus parameters and
associated activity states used for functional connectivity ﬁngerprinting. GCaMP activity is recorded for 10 min in the absence of light stimuli (pre-stimulus
state). Seizure-inducing white light stimuli are then applied every two minutes. GCaMP recordings during this period are subdivided into early post-
stimulus (0–60 s after the stimulus) and late post-stimulus (60–120 s after the stimulus) states during subsequent analysis. b Representative local ﬁeld
potential recordings (LFP traces; upper panels) and single frames from brain-wide GCaMP recordings (GCaMP activity; lower panels) in scn1lab mutants
(top) and wild-type controls (bottom) illustrating response to light stimuli at 5 dpf. LFP trances and GCaMP activity are recorded independently. Gray
bands on LFP recordings indicate the timing of the two 500ms light pulses. Scale bars show 0.5 s (x-axis) and 1 mV (y-axis). GCaMP images show activity
from a single z-plane 5 s before the ﬁrst pulse (pre-stimulus) and again 5 s after the second pulse (post-stimulus). Supervoxels with signiﬁcant changes in
ﬂuorescence activity (ΔF/F) are shown in color. c For each compound, a 165-metric functional connectivity ﬁngerprint is generated based on correlation
coefﬁcients between active supervoxels in all 55 pairs of brain areas during each of the three activity states. Each square represents the deviation of the
correlation for the compound in question (X) from the mean correlation for all compounds (Xmean) in the brain area pair being analyzed, normalized by
standard deviation [(X−Xmean)/XSTD]. The analysis is carried out in both mutants (Mut, magenta text) and sibling controls (WT, cyan text) prior to
compound addition (0 h) and again at 4 h post-exposure to the compounds in 1 % DMSO (4h). Fingerprints are analyzed by hierarchical clustering to
identify compounds that modulate functional connectivity networks in similar ways. We identify the three most distinct clusters (C1, C2, and C3) that fall
closest to the wild-type cluster. We then select the compound in each activity cluster that most effectively restores functional connectivity in scn1lab
mutants based on Euclidean distance from the wild-type cluster (indicated by checkmarks). Source data are provided as a Source Data ﬁle
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clustering to compare functional connectivity networks in drug-
treated larvae. When cluster analysis is carried out on compound-
treated wild-type controls, we observe a tendency for drugs with
related mechanisms of action to cluster together (Supplementary
Fig. 7). For example, both selective serotonin reuptake inhibitors
(SSRIs; ﬂuoxetine and ﬂuvoxamine) in our library localize to
Cluster 1, four out of ﬁve benzodiazepines (alprazolam, clobazam,
clonazepam, and diazepam) along with two another GABA
agonists (allopregnanolone and stiripentol) localize to Cluster 3,
and both glutamate receptor antagonists (L-701,324 and MPEP)
localize to Cluster 4. However, we note that there are also a
number of other drugs that do not cluster according to their
MOA, perhaps indicating an incomplete mechanistic under-
standing of their in vivo effects.
Adding scn1lab mutants to the analysis allows us to compare
functional connectivity between wild-type and mutant networks.
As expected, untreated siblings and untreated mutants localize to
highly divergent clusters on the resultant dendrogram, conﬁrming
that the activity proﬁles of these two groups are strikingly different
(Fig. 2c, Supplementary Fig. 8 and Supplementary Fig. 6).
Importantly, multiple independently-imaged groups of untreated
siblings (labeled WT-0h on Fig. 2c) cluster with one another, as do
multiple independently-imaged groups of untreated mutants
(Mut-0h on Fig. 2c), verifying that functional connectivity patterns
are relatively uniform for a given experimental condition and
therefore provide a robust basis for assessing neuromodulators.
Ranking connectivity ﬁngerprints based on Euclidian distance
from untreated sibling controls reveals that all 24 compounds
produce proﬁles in mutants that are at least somewhat closer to
siblings than to untreated mutants, consistent with the fact that
these compounds were selected based on efﬁcacy in a preliminary
behavioral assay (Supplementary Table 2).
To maximize the chances of achieving synergistic efﬁcacy in
polytherapy, each drug employed should correct distinct aspects of
the underlying disorder. Combining multiple drugs that target the
same pathological features is likely to increase side effects while
producing little additional therapeutic beneﬁt. Choosing drugs
with different known MOAs is a common strategy to achieve this
result, albeit an imprecise one that depends on an accurate
understanding of all biological targets of the drugs. Connectivity
ﬁngerprints provide a detailed multi-parametric readout of a
compound's actual in vivo effects that can be easily benchmarked
against wild-type controls, making them an attractive alternative
to MOAs for polytherapy selection. In order to identify
polytherapy candidates from our screen that are likely to
normalize complementary facets of the underlying pathology, we
devised a selection strategy based on multiple rounds of
hierarchical cluster identiﬁcation and elimination. Starting with
our initial connectivity ﬁngerprint dendrogram, we ﬁrst identify
the closest cluster to the cluster of untreated sibling control
(designated C1 on Fig. 2c). We then select the compound on this
cluster that is most effective at normalizing connectivity in scn1lab
mutants based on distance from the sibling cluster (mifepristone
in this case). In the next step, we eliminate all compounds that
localize to this cluster from further analysis. Regardless of their
MOA, these compounds modulate pathological brain activity in a
highly similar manner and therefore represent poor candidates for
pairing with the top hit in a polytherapy regimen. We then
perform a new round of clustering on the remaining compounds
and repeat the previously described selection process to identify a
new hit. The second and third rounds of compound selection and
cluster elimination identiﬁed ﬂuoxetine and clobazam as top hits,
respectively (Supplementary Fig. 9). As expected based on their
ability to differentially modulate functional connectivity networks,
each of these three compounds belongs to different drug classes
(Supplementary Table 1).
Algorithmic combinatorial screening for superior polytherapy.
Having reduced the polytherapy parameter space to a manageable
size, we evaluated all duotherapy combinations for both efﬁcacy
and behavioral side effects over a range of doses. This was done
using LFP recordings to quantify spontaneous seizures and
automated behavioral phenotyping to detect compound-induced
alterations in multiple locomotor parameters. We tested all pos-
sible pairwise combinations of our top three hits (clobazam,
ﬂuoxetine, and mifepristone) in both assays using a semi-log
range of doses: 10, 30, and 100% of the concentration used for
light-sheet screening. For LFP analysis, we assessed the ability of
each individual compound and duotherapy combination to
reduce spontaneous seizures in mutants using an automated
seizure detection algorithm we previously developed based on
methods for analyzing EEG signals33,46. Baseline seizure fre-
quency was ﬁrst determined for each larva during a 45-min pre-
exposure LFP recording. Seizure frequency was measured again
during a second recording beginning at 4+ hours post-exposure
and an efﬁcacy score was calculated by normalizing the post-
exposure frequency to the baseline frequency (Supplementary
Table 3, Efﬁcacy column).
In order to measure compound-induced side effects and
behavioral alterations, we performed an in-depth behavioral
assessment for all 36 treatment conditions relative to untreated
(1% DMSO-only) scn1lab mutants. Behavioral assessment was
carried out in 96-well plates using an automated video tracking
system and algorithms we developed previously33. Compounds
were applied directly to the wells and 30-min video recordings
were carried out at ~4 h post-exposure. We then automatically
quantiﬁed six distinct behavioral features related to swimming
velocity and tail motion for each larva: (1) Mean forward
swimming velocity, (2) Mean angular swimming velocity, (3)
Standard deviation of the angular swimming velocity, (4) Time
spent at high swimming velocity, (5) Mean tail bending angle,
and (6) Mean change in tail angle. All behavioral features were
normalized to baseline levels in untreated mutants (Supplemen-
tary Table 3, Behavioral Metrics columns). An overall side effect
score was then deﬁned for each treatment condition by
determining how much each behavioral feature diverged from
its baseline value in untreated controls and calculating the root
mean square of all six divergences (Supplementary Table 3,
Divergence from Baseline and Side Effect columns). The side
effect score therefore measures the overall magnitude of
behavioral changes triggered by an individual compound or
duotherapy combination.
LFP and behavioral assessments conﬁrm that polytherapy
combinations identiﬁed by connectivity ﬁngerprint analysis are
able to achieve signiﬁcantly greater efﬁcacy than any mono-
therapy alone (Fig. 3, Supplementary Table 3). Our data also
clearly shows that combining the top hits from a behavioral
screen alone, even after selecting those with different known
MOAs, performs far worse than our connectivity-based poly-
therapy (Supplementary Fig. 12). Importantly, a number of
duotherapy regimens show signiﬁcantly greater therapeutic
efﬁcacy at lower total concentrations while maintaining side
effect proﬁles comparable to monotherapies. Fluoxetine-
mifepristone duotherapy appears to be particularly effective, with
multiple lower-dosage combinations displaying substantially
greater efﬁcacy than even the highest doses of either drug on
its own (Fig. 3, Supplementary Video 7).
To test whether polytherapy indeed restores normal brain
connectivity better than monotherapy, we carried out light-sheet
imaging on mutants treated with ﬂuoxetine or mifepristone alone
at 100% concentration and compared the results with one of our
optimal duotherapy regimens (30% ﬂuoxetine, 30% mifepris-
tone). Larvae were assessed under the light-stimulus parameters
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described previously (Fig. 2a) and connectivity ﬁngerprints were
generated for each drug regimen. To evaluate the ability of
neuromodulators to restore resting state functional connectivity
patterns, we ﬁrst identiﬁed all signiﬁcantly correlated pairs of
brain areas in wild-type larvae (24 out of 55 total pairs; Fig. 4a).
For each pair of areas, we then calculated the resting state
divergence in connectivity (i.e. distance from wild-types in the
resting state) for each drug regimen (Fig. 4b–e; Supplementary
Fig. 10a). In addition, we calculated the divergence in connectivity
in the other two behavioral states (i.e. early post stimulus and late
post stimulus) for each drug regimen (Supplementary Fig. 10b–c).
Functional connectivity differed substantially from wild-type
larvae in nearly all brain area pairs in untreated (DMSO) scn1lab
mutants (Fig. 4b). Out of the 24 connections evaluated, 11 showed
decreased connectivity and eight showed increased connectivity
relative to wild-types, while ﬁve connections were not altered
signiﬁcantly. Both ﬂuoxetine and mifepristone alone reduced
abnormal connectivity patterns to varying degrees, however their
efﬁcacy was dramatically increased when used in combination
(Fig. 4e; Supplementary Fig. 10).
Discussion
There is a growing consensus that most neurological and psy-
chiatric disorders are associated with large-scale dysfunction of
brain connectivity47. In epilepsy, pathologic networks have been
used to explain seizure generation and spread, cognitive impair-
ment, and therapeutic response20. fMRI studies, sometimes
paired with simultaneous EEG, provide clear evidence for func-
tional connectivity network abnormalities in epileptic brains48.
The epileptogenic network in temporal lobe epilepsy (TLE), the
most common type of epilepsy, has been extensively character-
ized. Many fMRI studies report decreased connectivity in patients
with TLE relative to healthy controls, although there are also
indications of increased connectivity between some areas48. The
literature remains divided over the precise nature of these
changes, with some studies reporting decreased connectivity
within the epileptogenic region and increased connectivity to
other areas of the brain (perhaps reﬂecting compensatory
mechanisms)49,50, while others report the opposite pattern51. In
addition to altered connectivity, there is evidence that anti-
correlated activity in areas outside the epileptogenic region may
represent a protective adaptation that helps to limit seizure
spread52. Taken as a whole, these ﬁndings demonstrate that
epilepsy disrupts neural connectivity patterns throughout the
brain, causing both compensatory adaptations and deleterious
changes in the functional network. Functional connectivity
therefore represents a direct and exceptionally rich method for
assessing the underlying pathologies of epilepsy and other neu-
rological disorders. As such, new approaches for analyzing net-
work connectivity hold great promise for both clinical diagnosis
and drug discovery.
In the present study, we describe a high-throughput platform
for functional connectivity analysis and report for the ﬁrst time
that neuronal network dysfunctions similar to those observed in
human patients underlie epilepsy in a vertebrate model (zebra-
ﬁsh) that is amenable to large-scale screening. Our approach to
analyzing functional brain connectivity in GCaPM5-expressing
scn1lab mutant zebraﬁsh larvae builds on strategies that have
been successfully employed in humans to compare connectivity
between healthy controls and epileptic patients using fMRI53,54.
As in human studies, we begin by segmenting the registered
GCaMP recordings into areas based on a 3D anatomical brain
atlas. However, rather than averaging all voxels within each area
prior to correlation analysis, the superior spatial resolution
afforded by the GCaMP signal allows us to directly analyze all
spatially distinct supervoxels (presumably corresponding to
individual neurons) within each area. Additionally, the ability to
optically trigger seizures on demand in scn1lab mutant zebraﬁsh
enables us to assess connectivity during distinct, pathologically
relevant brain activity states. The resultant connectivity ﬁnger-
prints offer a highly accurate multi-state, multi-parametric tool
that readily distinguishes between wild-type and mutant larvae, as
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Fig. 3 Network-engineered polytherapy achieves superior therapeutic outcomes. Semi-log dose-response data showing efﬁcacy scores (cyan) and side
effect scores (magenta) for ﬂuoxetine and mifepristone alone (monotherapy) and combinatorially over all investigated doses (polytherapy) at ~4 h post-
exposure. For each compound, the highest dosage (100%) corresponds to the concentration used in the initial light-sheet-based screen (see
Supplementary Table 1). Efﬁcacy is calculated from local ﬁeld potential recordings using an automated seizure detection algorithm to count spontaneous
seizures over a 45-min interval. The side effect score is based on six distinct behavioral metrics quantiﬁed over a 30-min interval using an automated video
tracking platform. Both scores are determined under resting state conditions (i.e. in the absence of light stimuli) and calculated as described in Methods.
Scores have been normalized to untreated age-matched larvae (n= 5+ larvae per condition for efﬁcacy; n= 10 larvae per condition for side effect). Several
polytherapy combinations show substantially greater therapeutic efﬁcacy while maintaining behavioral proﬁles that are in the same range as monotherapy
regimens. The combination of ﬂuoxetine and mifepristone, both at the 30% dosage (optimal combination), is signiﬁcantly more effective than either
mifepristone alone (p= 0.000106; unpaired two-tailed Student's t-test) or ﬂuoxetine alone (p= 0.000105; unpaired two-tailed Student's t-test) at the
same dosages. The error bars represent standard deviation. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10541-1 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2620 | https://doi.org/10.1038/s41467-019-10541-1 | www.nature.com/naturecommunications 7
conﬁrmed by cluster analysis (Fig. 2c, Supplementary Fig. 6). The
classiﬁcation accuracy of our approach when compared with
similar attempts in human patients undoubtedly beneﬁts greatly
from the ability to control virtually all experimental conditions:
the zebraﬁsh larvae used are medication-naive age-matched sib-
lings and their seizures are driven by a common mutation to a
single human disease-associated gene.
Using our high-throughput platform, we go on to demonstrate
how brain-wide functional connectivity analysis can be utilized to
overcome the massive combinatorial challenge of polytherapy
screening. By classifying drugs based on their actual in vivo effects
on brain networks, we are able to identify highly effective can-
didates for combination therapy even in the absence of infor-
mation on underlying MOAs. Such an empirical approach to
polytherapy selection based on connectivity analysis has the
potential to beneﬁt patients suffering from a broad range of
disorders. In addition to epilepsy, aberrant functional con-
nectivity networks have been associated with autism21,22,
schizophrenia23,24, major depressive disorder25, post-traumatic
stress disorder26, bipolar disorder55, and attention-deﬁcit hyper-
activity disorder56 among others. Moreover, connectivity can be
monitored using a variety of readouts (calcium signals, fMRI,
high-density EEG) that are suitable for animal screens and even
human studies. Our connectivity-based approach to assessing and
classifying neuromodulators can therefore be applicable to a wide
range of disease models and may even prove useful for the clinical
implementation of personalized medicine in neuropsychiatric
disorders.
Although neither of the drugs in our network-engineered
polytherapy regimen is classiﬁed as an AED clinically, antic-
onvulsant effects have been reported for ﬂuoxetine (Prozac),
which is an antidepressant of the selective serotonin reuptake
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Fig. 4 Network-engineered polytherapy restores resting state brain connectivity in mutants. a Diagram depicting brain areas with statistically signiﬁcant
absolute correlation values (unpaired two-tailed Student's t-test; p < 0.05 considered signiﬁcant; normality of datasets was tested using the Jarque–Bera
normality test) in wild-type larvae at 5 dpf (n= 10). Only these connections are shown in b–e. b–e Diagrams illustrating alterations in functional brain
connectivity in scn1lab mutant larvae with respect to wild-type sibling controls under the following conditions: b untreated mutants (DMSO), c mutants
treated with ﬂuoxetine alone at the 100% dose, d mutants treated with mifepristone alone at the 100% dose, and e mutants treated simultaneously with
ﬂuoxetine and mifepristone using one of the optimal polytherapy dose regimens (both drugs at 30%). For all diagrams, brains are shown from the left side
(left), from the dorsal side (center), and from the right side (right). Connections which increase or decrease with respect to wild-type larvae are indicated
with blue or red lines, respectively. The thickness of the lines in b–e indicates the magnitude of deviation from normal wild-type connectivity. Functional
connectivity for each pair of brain areas is determined at 4+ h post exposure by calculating the average absolute correlation between active supervoxels
within each area during the pre-stimulus states. For each compound, the highest dose (100%) corresponds to the concentration used in the initial light-
sheet-based screen (see Supplementary Table 1). Ten larvae were analyzed per condition. Ce, cerebellum; HBl, hindbrain left; HBr, hindbrain right; OBl,
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thalamus (For ease of illustration, the areal labels/borders are not always shown on anatomically correct positions/scales)
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inhibitor class. According to a recent report, ﬂuoxetine was
effective in markedly reducing seizures in an adult woman with
Dravet syndrome who had previously failed to respond to
numerous other AEDs57. Additionally, ﬂuoxetine has been shown
to exhibit anticonvulsant effects when administered either acutely
or as a dietary supplement in a variety of rodent seizure mod-
els58–61. Of particular interest in light of our observations, there
are indications that ﬂuoxetine may be able to increase the
anticonvulsant activity of several common AEDs, including car-
bamazepine, phenobarbital, diphenylhydantoin, and valproate,
against PTZ-induced seizures62 and in the maximal electroshock
seizure model in mice61. The second drug in our polytherapy
regimen is mifepristone (RU-486), a synthetic steroid that acts as
an antagonist of both the progesterone and glucocorticoid
receptors in mammals63 and in zebraﬁsh64,65. Anticonvulsant
effects have not previously been associated with mifepristone,
however there is ongoing interest in targeting glucocorticoid
receptors in patients with epilepsy due to the pro-convulsant
actions of stress hormones such as cortisol66. Our data in zeb-
raﬁsh indicate that additional investigation of both ﬂuoxetine and
mifepristone—or related compounds—is warranted in Dravet
syndrome and other epilepsies. More generally, our results point
to the need to look beyond monotherapy regimens and to utilize
more sophisticated readouts that capture the full complexity of
epilepsy and other CNS disorders in future drug screens.
It is also worth mentioning that our functional connectivity
analysis alone does not imply that a drug cocktail should always
lead to behavioral improvement. Rather, it identiﬁes a cocktail
that corrects network functional connectivity: In rare cases, cor-
rection of functional connectivity may not imply the correction of
all phenotypes. For example, carbamazepine ranks highly in our
connectivity analysis because it indeed normalizes particular
aspects of functional connectivity, however our additional LFP
analysis33 indicates this particular drug doesn’t improve seizure
in zebraﬁsh. Thus, our functional connectivity analysis should be
complemented with other metrics, such as behavioral and LFP
analysis, as we did previously33.
Methods
Fish maintenance. All procedures on live animals were approved by the Massa-
chusetts Institute of Technology Committee on Animal Care. The scn1labs552 line
(also known as double indemnity or didy) has been described previously16 and was
crossed onto a line expressing the genetically encoded calcium indicator
GCaMP5G39 under the control of the pan-neuronal elavl3/HuC promoter [Tg
(HuC:GCaMP5G); a generous gift of A Schier, Harvard, Cambridge, MA].
Homozygous mutant scn1labs552 larvae and age-matched sibling controls expres-
sing the GCaMP5G reporter were obtained by crossing Tg(HuC:GCaMP5+/+;
scn1lab+/−) adults. Adult ﬁsh were maintained under standard laboratory condi-
tions and larvae were staged as described67. Fertilized eggs were generated by
crossing heterozygous adults and raised on a 12 h light/12 h dark cycle at 28 °C in
E3 medium (5mM NaCl, 0.17mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, pH 7.2).
0.2 mM 1-Phenyl-2-thiourea (PTU) was added to the embryo medium to inhibit
melanogenesis68 and allow optical imaging of the brain for light-sheet experiments.
For LFP and behavioral experiments, homozygous mutant scn1lab larvae were
identiﬁed based on the presence of dispersed melanosomes69. Because PTU
prevents the use of the pigmentation phenotype to identify homozygous mutants,
all larvae used in light-sheet imaging experiments were genotyped post-imaging
using the Derived Cleaved Ampliﬁed Polymorphic Sequences (dCAPS) method to
detect the scn1labs552 mutation70. PCR conditions consisted of 37 cycles of 95 °C
for 20 s, 60 °C for 20 s, and 68 °C for 30 s. The following PCR primers were used for
the dCAPS assay, resulting in the introduction of an BamHI-sensitive restriction
site in the mutant but not the wild-type scn1lab allele.
Forward: TGCTCAGGCTGTGTGATGAGG
Reverse: TCACCAGTGCTCCGCTGCTGAGTAGGATC
Dual-layer agarose embedding. To securely immobilize and precisely position
non-anesthetized non-paralyzed zebraﬁsh larvae for extended light-sheet imaging
sessions, we devised a process through which larvae can be embedded in a cylinder
of 1.3% ultra-low gelling temperature agarose (which solidiﬁes at 25 °C; A2576,
Sigma) surrounded by shell of 2% low gelling temperature agarose (which solidiﬁes
at 55 °C; A0701, Sigma). The ultra-low gelling temperature core allows larvae to be
safely added to the agarose while in a liquid state without being exposed to
excessive temperatures. The more rigid low gelling temperature agar shell
strengthens and supports the inner core, allowing it to be inserted into the glass
capillary and ensuring that the larvae are fully immobilized. Embedding is
accomplished by ﬁrst transferring larvae into a solution of liquid 1.3% ultra-low
gelling temperature agarose, which is then poured into a 20 mL syringe. The 20 mL
syringe is then inserted into a 60 mL syringe ﬁlled with 2 % low gelling temperature
agarose. The 20 mL syringe is capped with an 18-gauge stainless steel needle and
the 60 mL syringe is capped with a 16-gauge stainless steel needle. We then
simultaneously extrude both agarose solutions into a room temperature bath
containing E3 medium, allowing the agar to rapidly solidify.
High-throughput light-sheet microscopy screening platform. The illumination
and detection arms of our platform build on previous designs for laser-scanning
light-sheet microscopes30. We use a 488 nm 100 mW low-noise collimated diode
laser (LLD-0488, Laserglow Technologies, Toronto, Canada) with tunable power
supply to generate the excitation laser beam. The light sheet is created by a 2D
galvanometer-based scanner (6210H, Cambridge Technology, Cambridge, MA)
and a tube lens (ITL200, Nikon, Tokyo, Japan). A ×4/0.1 NA objective lens (Nikon,
Tokyo, Japan) is used to illuminate the sample with the light sheet. A second ×4/0.1
NA lens is used to direct the seizure-inducing light pulses, which are generated
using a Quartz Tungsten-Halogen lamp (QTH10/M, Thorlabs, Newton, NJ) gated
by a stepper-motor driven shutter and microprocessor-based controller (Smart-
Shutter and Lambda SC controller, Sutter Instrument Company, Novato, CA).
Emitted light is detected with a ×16/0.8 NA water immersion objective (Nikon)
mounted on a piezo-driven nanofocusing device (P-725 PIFOC, Physik Instru-
mente, Auburn, MA) followed by 525/50m emission ﬁlter (Chroma Technology,
Bellows Falls, VT) and a tube lens (ITL200, Nikon). Images are captured on a
sCMOS camera (ORCA-Flash4.0 V2, Hamamatsu Photonics, Hamamatsu, Japan).
For functional connectivity analysis, images are captured with 4 × 4 binning at 50
frames per second with a 2 ms exposure time. The structural images used for
registration to the anatomical atlas are captured at a higher resolution with 2 × 2
binning and a 20 ms exposure time. The camera is controlled through a custom-
made program that uses the Hamamatsu plugin for LabVIEW (National Instru-
ments, Austin, TX).
To facilitate the light-sheet-based screening of compound libraries, we
developed peripheral ﬂuidics that allow zebraﬁsh larvae under multiple treatment
conditions to be repeatedly imaged with a near-continuous workﬂow
(Supplementary Fig. 1). Our setup consists of an array of incubation chambers,
which are fabricated by removing the ﬁlters from size exclusion spin columns
(#7326227, Bio-Rad, Hercules, CA). Chambers are initially ﬁlled with 500 μL of E3
medium and used to hold larvae that have been embedded in dual-layer agarose
cylinders as described in the previous section. Incubation reservoirs are held in an
array of holes drilled into a 5 mm thick plexiglass holder (McMaster-Carr,
Elmhurst, IL, USA). Separate peristaltic tubing lines (1.47 I.D. HelixMark silicon
tubing, catalog #60–011–06, VWR, Radnor, PA) gated by pinch valves (B4M, Hach,
Loveland, CO) are attached to openings at the top and bottom of each incubation
chamber. The upper tubing supplies air at 5 PSI when the incubation chambers are
drained. All lines from the bottom openings of the incubation chambers are
connected to a master peristaltic tube line (1.98 I.D. HelixMark silicon tubing,
catalog #60–011–09, VWR), which in turn is connected to an automated 10 mL
syringe pump (Cavro 20738449; Tecan, Männedorf, Switzerland) with E3 medium
at one end and a thin-wall fused silica glass capillary (Index of reﬂection of 1.458, 1
mm I.D., 10-SG-1, Charles Supper Company, Natick, MA) at the other end. This
glass capillary serves as the imaging chamber and runs through the center of a 1 ×
1 × 1 inch3 custom fabricated aluminum chamber (RM1G, Thorlabs). Mounting
holes for the capillary are ﬁtted with a pair of quarter-inch bearing balls (01376748,
MSC Industrial Supply, Melville, NY) in order to create a water-tight seal around
the capillary and allow the aluminum chamber to be ﬁlled with water for the water
immersion objective. A stepper motor (Nema 17 High Torque Stepper Motor) is
used to rotate the capillary and control the angular position of the larva in the
imaging chamber. The end of the capillary opposite that which the larva enters is
connected to peristaltic tubing (1.47 I.D. HelixMark silicon tubing, catalog
#60–011–06, VWR), which contains a pinch valve to regulate ﬂow (B4M, Hach)
and attaches to a three-way syringe pump (Cavro 20738449; Tecan). The three-way
pump in turn is attached to (1) the vacuum that collects the excess liquid used to
wash the imaging chamber after each imaging cycle and (2) a 10 mL syringe that is
used to control the lateral position of larva in the imaging chamber.
To load larvae from one of the incubation reservoirs into the imaging chamber,
the glass capillary is ﬁrst ﬂushed to remove any residual liquid from the previous
imaging step. This is done by opening pinch valves A1 and B1 and transferring
1 mL of E3 medium from syringe pump A into syringe pump B. Both pinch valves
are then closed and the E3 medium is expelled from syringe pump B into a vacuum
ﬂask. To load larvae from the n-th incubation reservoir in the array, we open pinch
valves Vn, A2, and B1. Syringe pump B then drains liquid from the n-th reservoir
until the ﬁrst larva is in the imaging chamber. When the larva is in the place, pinch
valves Vn, A2, and B1 are closed. After the imaging session is completed, all three
valves are opened and continue draining the reservoir until the next larva enters the
imaging chamber. This process is repeated until all larvae contained in the n-th
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incubation reservoir have been imaged, at which point pinch valves are opened and
the larvae are transferred back into the incubation reservoir using syringe pump B.
After completion of the initial pre-drug-exposure imaging session, 500 μL of the
test compound (2x working stock prepared in E3 medium; 2 % DMSO) is added to
the incubation reservoir. This brings the total reservoir volume to 1 mL, resulting in
the indicated screening concentrations (Supplementary Table 1) and a ﬁnal DMSO
concentration of 1 %. At 4+ h post-exposure, all larvae in the incubation reservoir
are once again loaded into the imaging chamber for a second imaging session
following the same procedure as before. Once the second imaging session is
complete, larvae are collected for PCR genotyping.
Image processing and cluster analysis. We created a custom 3D anatomical
brain atlas based on high-resolution (1024 × 1024 pixel) structural images obtained
from GCaMP5-expressing zebraﬁsh larvae at 5 dpf. Structural images were
acquired from 20 slices in steps of 20 μm along the z-axis (i.e. the dorsal–ventral
axis of the larva) over the course of a ~4 min recording. Manual segmentation was
carried out based on anatomical landmarks with the aid of the Atlas of Early
Zebraﬁsh Brain Development71 and the Z-Brain Atlas72. Segmentations were
performed using ZBrainViewer72.
To facilitate registration of GCaMP5 recordings to our 3D reference atlas, we
ﬁrst acquire a high-resolution structural reference image of each brain prior to
functional activity imaging. Reference images are generated by calculating the
average of the voxel baseline over a 200-s interval at the start of each image
acquisition. As with structural images used for the brain atlas, these reference
images are acquired at 1024 × 1024 pixels (1100 μm× 1100 μm ﬁeld of view) from
25 slices in steps of 20 μm along the z-axis. The brain is extracted from the
background in each image with the FSL Brain Extraction Tool73 using a threshold
on the intensity level. The start of the stack is selected automatically using
automated landmark detection to identify the dorsal surface of the optical tectum.
The high-resolution reference image is then downsampled and resliced to 256 ×
256 pixels. This volumetric 3D reference image is next aligned to the corresponding
plane in the structural images from the atlas by rigid transformation using the
automated volume-based Advanced Normalization Tools (ANTs) software
package74 in Matlab (Mathworks, Natick, MA) to obtain a rough alignment. The
rigid transformation is then applied to the original high-resolution reference image.
In the second step, the high-resolution reference image is registered to the atlas
structural image using afﬁne transformation. We then compare the accuracy of our
segmentation algorithm to that of manual segmentation (Supplementary Table 5).
Our result shows our algorithm is highly accurate for clustering ﬁngerprints
(Supplementary Fig. 11). To demonstrate the segmentation is sufﬁciently accurate,
we calculated the clusters after randomly modifying the segmentation such that the
new segmentation has only 95% overlap with the original segmentation and then
we measured the distance between the original C1, C2 (Supplementary Fig. 11a)
and C3 (Supplementary Fig. 11b) clusters from Fig. 2c. Our results show even 10%
error in the segmentation does not signiﬁcantly change the clusters.
After the acquisition of the high-resolution structural images, we perform high-
speed functional recordings using reduced resolution 512 × 512 pixel images from
10 slices in steps of 40 μm along the z-axis, resulting in a brain-wide imaging rate of
20 Hz. Based on our depth of ﬁeld (9.5 μm per slice) and the distance between
planes, we cover a total scanning range of ~120 μm along the z-axis (i.e. the
dorsal–ventral axis). In order to determine functional connectivity between brain
areas, we begin by ﬁrst identifying all voxels that show time-varying activity during
the pre-stimulus state. For each voxel, we deﬁne the time-averaged signal as:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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where f is the vector of intensity of the voxel time, T is the number of samples over
time, and f0 is the average of f over time. Since a single neuron may be covered by
multiple voxels, we combine signals from highly time-correlated adjacent voxels
using k-means clustering where the number of voxels is determined by k-fold
cross-validation43, resulting in a list of all spatially distinct supervoxels. We then
ﬁnd the correlation coefﬁcient between active supervoxels for all pairs of areas
during each of the three behavioral states. A voxel is considered non-time-varying
if its time-averaged signal is ≥1 standard deviation below the mean time-averaged
signal of all voxels in the same slice. Since a single neuron may be covered by
multiple voxels, we combine signals from highly time-correlated adjacent voxels
using k-means clustering where the number of voxels is determined by k-fold
cross-validation43, resulting in a list of spatially distinct supervoxels with co-
varying activity. We then identify active supervoxels that show a signiﬁcant change
in GCaMP5 ﬂuorescence (ΔF/F). The threshold level for active supervoxel
detection in each slice is determined using an open source calcium imaging
processing toolbox for the analysis of neuronal population dynamics75 by ﬁtting a
Gaussian process to each supervoxel resting-state time series. Detected supervoxels
have an average diameter of 7.1 ± 3.2 μm (mean ± SD), consistent with the size of
individual cell bodies. On average, we detect 14,950 ± 583 (mean ± SD) total
supervoxels per brain (n= 50 GCaMP recordings from independent larvae) of
which ~10 % are designated as active supervoxels. Zebraﬁsh larvae are estimated to
have on the order of 105 neurons76. Assuming that each supervoxel corresponds to
an individual neuron, we are able to detect ~15% of all neurons, consistent with the
fraction of brain that is covered based on our imaging parameters (~9.5 μm thick
slices acquired in steps of 40 μm).
Functional signals are extracted from the volumetric data based on the relative
change in GCaMP5 ﬂuorescence (ΔF/F). The baseline for each supervoxel (F) is
measured by averaging intensity over a 20-s sliding window. We next divide each
functional recording into the following three activity states: (1) Pre-stimulus (an
initial 10-min resting state recording in the absence of light stimuli), (2) Early post-
stimulus (10–60 s after presentation of seizure-inducing light stimuli; the ﬁrst 10 s
after stimuli is removed from analysis to increase the stationarity of signal), and (3)
Late post-stimulus (60–120 s after presentation). We then determine the mean
absolute correlation coefﬁcient, for each pair of brain areas (e.g. area A and area B)
during each of the three activity states as follows. We calculate the mean absolute
Pearson’s correlation30 over all the pairs of voxels from area A and B (A vs B
correlation).
Here, we demonstrate that the correlation analysis of active supervoxel pairs
outperforms a simpler global pooling. First, we calculated the correlation
coefﬁcients of global pooling as suggested and then used the results for compound
clustering. To compare the quality of clusters, we measured two metrics: the
distance between wild type cluster and mutant cluster (BCD, the larger the better),
and the distance within the wild type cluster (WCD, the smaller the better). Our
results show that both metrics deteriorate when we use global pooling instead of
voxel correlation: BCD decreases by ~56% (from 1.62 to 0.91) and WCD increases
by ~110% (0.38–0.80). Furthermore, we demonstrate that BCD/WCD ratio
decreases if larger voxels were used (Supplementary Fig. 13).
In order to verify that we are analyzing sufﬁcient numbers of neurons per brain
area, we tested the stability of functional connectivity metrics. First, we calculate
the correlation coefﬁcient under resting conditions (i.e. the 10 min prior to the
presentation of seizure-inducing light stimuli) between a pair of brain areas over all
active supervoxels. Then, we randomly group the supervoxels in each brain area
into two subgroups and recalculate the inter-area correlation coefﬁcients for each
subgroup and calculate the difference in correlation. This process is repeated 50
times for each pair of brain areas. We then test if there is a signiﬁcant difference
between the correlation coefﬁcient group differences. The median of the p-values
for all 55 brain area pairs in 10 scn1lab mutants indicate no signiﬁcant differences
in correlation coefﬁcient across different subgroups of supervoxels (p < 0.05;
n= 10).
In order to verify that our time series connectivity data are stationary, we
analyzed GCaMP recordings from 10 scn1lab mutants and 10 wild-types during
the pre-stimulus resting state (i.e. the 10 min prior to the presentation of seizure-
inducing light stimuli) using the Priestley-Subba Rao test77. The analysis is
performed using an open source stationarity R package (https://rdrr.io/github/
gnardin/stationarity/src/R/priestley.subba.rao.test.R). Statistical tests for non-
stationarity require deﬁning a test statistic and an appropriate framework for
generating null data. Null hypothesis testing is then performed by comparing test
statistics from real data against those from null data. For each brain area pair, we
use multiple 5-min blocks assembled randomly from 30-s windows to assess the
second order stationary of the correlation coefﬁcient. We test the weak-sense
stationarity hypothesis of correlation (i.e. that its ﬁrst and second order ensemble
statistics are constant in time)78 by determining the variance (κ) of the sliding
window correlation (SWC):
κ ¼ 1
T  1
X
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where the correlation between two areas is calculated over 30 s windows, SWC(t) is
the SWC at time t, and μ is the mean of the SWC time series. Larger κ values
relative to the null distribution suggest non-stationarity (i.e. dynamic connectivity).
We generate null data by ﬁtting a second order autoregressive randomization
(ARR) process to the SWC time series. Data from the original time series are then
tested against the ARR null data. In this test, the null hypothesis corresponds to
dynamic connectivity. Therefore, If the two datasets are not signiﬁcantly different
(p < 0.05) the null hypothesis is rejected and the original data are assumed to be
stationary. For all 20 larvae analyzed, the median p-value of the second order
stationarity test for the 55 area pairs was <0.05. On average, time series connectivity
data from ~51 of 55 (93%) brain area pairs per larva were found to be stationary
(p < 0.05; unpaired Student's t-test) (Supplementary Table 4).
Hierarchical cluster analysis of functional connectivity ﬁngerprints is performed
using Scikit-learn (http://scikit-learn.org/stable).
Behavioral analysis. Locomotor activity is recorded using a custom-built video
tracking system consisting of a monochrome CCD camera (Prosilica GX1050;
Allied Vision, Exton, PA) ﬁtted with a close-focusing macro video lens (Zoom 7000
lens system, Navitar, Rochester, NY), a near IR longpass ﬁlter (LP800–52, MidOpt,
Palatine, IL), and an IR, white light LED illuminator (BX 06 06 WHI/IR, Advance
illumination, Rochester, VT). The system is surrounded by a custom-made light-
tight optical table enclosure and mounted on an optical breadboard base. The IR/
LED illumination is controlled by an Arduino Mega 2560 microcontroller board
(digital output range from 0.0 to 5.0 volts; Adafruit Industries, New York, NY).
At 5 dpf, homozygous mutant larvae are separated from age-matched sibling
controls based on pigmentation69. Single larvae are distributed into individual wells
of ﬂat-bottomed 96-well microplates (MultiScreen 96-well Transport Receiver
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Plate, Millipore, Billerica, MA) in a volume of 100 μL of E3 medium per well and
the microplates are placed inside the imaging chamber. 2x working stocks of each
compound are prepared in E3 medium and the DMSO concentration is adjusted to
2%. 100 μL of the 2x working stock is added to each well (n= 10 larvae per
experimental condition), resulting in the indicated screening concentrations and a
ﬁnal DMSO concentration of 1%. Four hours after compound addition, a 30 min
locomotor activity recording is acquired.
The positions of all larvae are automatically detected in each frame using a
custom MATLAB tracking algorithm that we developed previously33. Brieﬂy, the
algorithm generates a binary image of all larvae and performs a skeletonization
step. The tip of the head and the tip of the tail are automatically identiﬁed and ﬁve
equally spaced vertex points are positioned along the detected centerline of each
larva. These ﬁve points are used to calculate six distinct behavioral features. The
two anterior-most points are used to deﬁne the body centerline and calculate
swimming velocity metrics while the three posterior-most points are used to deﬁne
the tail centerline and calculate tail-speciﬁc metrics. The mean forward swimming
velocity (FVmean; pixels s−1) is calculated based on the distance traveled by the larva
parallel to the body centerline. The mean angular swimming velocity (AVmean;
pixel s−1) and the standard deviation (SD) of the angular swimming velocity
(AVSTD; pixels s−1) are calculated based on the distance traveled by the larva
perpendicular to the body centerline. We set a high velocity swimming threshold
(values greater than FVmean+ FVSTD) and use this threshold to calculate the
percentage of time spent at high swimming velocity (HV%). The tail angle is
calculated for each tail vertex point and the absolute values of all points are
summed together. These values are used to calculate the mean tail bending angle
(TBmean; degrees). Mean change in tail angle (dTBmean; degrees s−1) is based on the
sum of change in tail angle for each tail vertex point. For each behavioral feature,
we calculate the mean of all 10 larvae and normalize this value to the untreated (1%
DMSO) mutant group (see Supplementary Table 3, Behavioral Metrics columns).
In order to calculate a combined behavioral score, we ﬁrst determine how much
each behavioral feature diverges from its mean baseline value in the untreated
mutant group (see Supplementary Table 3, Divergence from Baseline columns).
We then deﬁne the combined behavioral score (xcombined) as the square root of the
arithmetic mean of the squares of each of the six divergence values.
The combined behavioral score represents the root mean square of the
divergences and therefore serves as a measure of the magnitude of behavioral
changes that are triggered by a given compound or duotherapy combination
relative to baseline behavior in untreated larvae (see Supplementary Table 3, Side
Effect column). The standard deviation of the combined behavioral score is
obtained by ﬁrst calculating the divergence of each behavioral feature for each of
the 10 individual larvae in the condition of interest. A combined behavioral score is
calculated for each individual larva and the standard deviation of all 10 individual
scores is determined.
LFP recording and analysis. At 5 dpf, larvae are embedded in ultra-low gelling
temperature agarose. At least ﬁve larvae are recorded for each experimental con-
dition. Individual larvae are placed in a recording chamber with 50 mL of
E3 solution and a 45 min pre-exposure LFP recording is obtained. After the
baseline recording is complete, 50 mL of a 2x working stock of the test compound
(s) is added to the recording chamber. Following compound administration, a
second LFP recording is made 4+ h post-exposure. Recording electrodes are made
by pulling a 1 mm outer diameter capillary (BF100–78–10, Sutter Instrument
Company, Novato, CA), which is ﬁlled with 1M chloride solution. A Ag/Cl wire
(64–1320, Harvard Apparatus, Holliston, MA) is then placed inside the electrode,
the electrode is connected to a preampliﬁer (RHD2216, Intan Technologies, Los
Angeles, CA), and the preampliﬁer is connected to a low-power digital acquisition
chip (RHD2000, Intan Technologies). The signal from acquisition board is
recorded using Intan MATLAB GUI software (MATLAB 13, Mathworks, Natick,
MA). The data are then analyzed using an automated seizure detection algorithm
originally developed to analyze EEG signals46, which we have adapted to zebraﬁsh
LFP recordings. The algorithm uses higher order statistical moments as features to
classify electrophysiological signals into seizure and non-seizure classes. Higher
order moments are extracted from intrinsic mode functions, which are obtained by
adaptively decomposing the signal using the empirical mode decomposition
(EMD) method. The automated seizure detection algorithm is trained to identify
seizures using LFP recordings from scn1lab mutants exposed to light stimuli as a
training dataset. We then use the algorithm to measure spontaneous seizure fre-
quency in compound-treated scn1lab mutants. Baseline seizure frequency is
determined for each larva based on the pre-exposure LFP recording. The post-
exposure frequency is then normalized to the baseline frequency and an efﬁcacy
score is calculated (untreated mutants= 0; seizure-free larvae= 1.00; Supplemen-
tary Table 3).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon request. The source data underlying Figs. 2c, 3, and Supplementary Figs. 1,
4, 11, and 13 and Supplementary Tables 2, 3, and 5 are provided as a ﬁle. The atlas is
available online from GitHub (https://github.com/rezaie99/NC-18-28140.git).
Code availability
Core source code, including (1) Python source code for motion correction and timeline
extraction of images, (2) Bash ﬁles to run external tools (ANT) for registration, (3) Python
code for frequency and synchronization analysis, (4) Python code for LFP analysis and
correlation, and (5) MATLAB code for cluster analysis and statistical calculation, is
available online from GitHub (https://github.com/rezaie99/NC-18-28140.git).
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